Search Hotels in Sausalito

GSK will invest $30 billion in U.S. R&D and manufacturing, including a new biologics factory, AI upgrades, and expanded drug and device capabilities.

Congressional Trading Report: Rep. David Taylor Sold Over $2K In Alphabet Stock ↗

September 17, 2025

Via Benzinga

GSK To Pour $30 Billion Into US R&D, Manufacturing Over Five Years ↗

September 17, 2025

Via Benzinga

Topics Artificial Intelligence

Eli Lilly Says Its Obesity Pill Topped Novo Nordisk’s Oral Drug In Late-Stage Diabetes Trial ↗

September 17, 2025

Why Is Eli Lilly’s Stock Slipping Premarket? ↗

September 17, 2025

Eli Lilly To Set Up $5B Facility In Virginia – More Details Inside ↗

September 16, 2025

Eli Lilly's orforglipron showed significant weight loss, improved blood sugar, and reduced inflammation in adults with obesity or overweight in a Phase 3 trial.

Could This Eli Lilly Oral Pill Be Key To Significant Weight Loss? ↗

September 17, 2025

Via Benzinga

Apple To Rally More Than 28%? Here Are 10 Top Analyst Forecasts For Wednesday ↗

September 17, 2025

Via Benzinga

This FedEx Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday ↗

September 17, 2025

Via Benzinga

Dow Futures Stall Ahead Of Fed’s Interest Rate Decision Today: WDAY, MSFT, GOOGL, NVDA Among Stocks To Watch ↗

September 17, 2025

While Dow Jones futures were up 0.03% at the time of writing, the S&P 500 futures fell 0.07%.

GSK Stock Climbs After-Hours On $30B US Investment Pledge As Trump Pressures Big Pharma To Build In America ↗

Topics ETFs Economy Government

September 16, 2025

The plan includes $1.2 billion for a new biologics factory in Upper Merion, Pennsylvania, along with AI upgrades and expanded drug production across existing U.S. sites.

A news article implied that the company might have an advantage in the weight loss drug race.

Topics Artificial Intelligence Government World Trade

Why Eli Lilly Stock Was a Winner Today ↗

September 16, 2025

Novo Nordisk Navigates a GLP-1 Gold Rush: Soaring Obesity Drug Sales Clash with Revised Outlook Amidst Mounting Competition

September 16, 2025

Copenhagen, Denmark – Pharmaceutical giant Novo Nordisk (NYSE: NVO) has reported a robust second quarter for 2025, with impressive revenue and net income figures largely propelled by the formidable...

The FDA finds Eli Lilly's video on Zepbound and Mounjaro misleading, citing omissions of serious risks.

Topics Earnings Economy Intellectual Property

FDA Flags Eli Lilly's Weight-Loss Drug Video For Misleading Claims ↗

September 16, 2025

Via Benzinga

Eli Lilly To Invest $5 Billion In New Virginia Manufacturing Facility To Support Cancer Drugs Manufacturing ↗

September 16, 2025

Eli Lilly plans a $5 billion Virginia facility to expand drug production, create 650 jobs, and use advanced tech for cancer and autoimmune treatments.

Via Benzinga

Wegovy's Next Step: Novo Nordisk Eyes Approval for Higher-Dose Treatment ↗

September 16, 2025

Novo Nordisk plans to seek FDA approval for a high-dose Wegovy, matching Eli Lilly's Zepbound with another weight-loss option for patients.

Via Benzinga

3 Undervalued Healthcare Stocks to Buy Now While They're Cheap ↗

September 16, 2025

In an otherwise hot stock market, healthcare stocks are underperforming.

Quality yields above 6% from three very different market sectors.

Forecasting The Future: 10 Analyst Projections For Eli Lilly ↗

September 16, 2025

Via Benzinga

3 Great High-Yield Dividend Stocks to Buy in September ↗

September 16, 2025

The weight loss drug market may reach $95 billion within five years.

Here Is My Top Stock Pick Among the Weight Loss Industry Leaders ↗

September 16, 2025

Novo Nordisk (NYSE: NVO) has once again demonstrated formidable strength in its obesity care segment, with powerhouse drugs Wegovy and Ozempic propelling the company to a robust Q2 2025 performance....

Novo Nordisk's Weight-Loss Wonders Drive Q2 Growth Amidst Shifting Sands of Competition

September 15, 2025

AstraZeneca Puts Cambridge Expansion On Ice Adding Pressure On Starmer Ahead Of Trump Visit ↗

Topics Economy Intellectual Property

September 15, 2025

AstraZeneca pauses its £200 million UK investment as rising costs, undervaluation, and unclear policies hinder pharma R&D and foreign capital inflows.

Via Benzinga

Topics Government

Novo Nordisk Faces Headwinds: Competitive Pressures and Compounded Drugs Force Lowered Outlook

September 15, 2025

Copenhagen, Denmark – Novo Nordisk (NASDAQ: NVO), the pharmaceutical powerhouse synonymous with diabetes and obesity care, has significantly pared back its full-year sales and profit projections for...

The Weight of Progress: A New Era Dawns for Anti-Obesity Drugs, Reshaping Markets and Health

Topics Economy Intellectual Property Law Enforcement

September 15, 2025

The global anti-obesity drug market is experiencing an unprecedented surge, driven by groundbreaking advancements in pharmacotherapy, particularly the advent of highly effective GLP-1 receptor...

A price cut could help get Novo Nordisk stock back in the race against Eli Lilly.

Why Novo Nordisk Stock Popped Today ↗

September 15, 2025

Eli Lilly has seen weakness in its stock price year to date. I think it's a short-term problem.

1 Stock That Should Be in Every Investor's Portfolio ↗

September 15, 2025

They could deliver market-beating returns beyond 2030.

3 Monster Stocks to Hold for the Next 5 Years ↗

September 14, 2025

Their prospects look intact despite some recent roadblocks.

Topics Artificial Intelligence

2 Beaten-Down Stocks to Buy and Hold Forever ↗

September 13, 2025

The "Magnificent Seven" stocks have done incredibly well over the past five years, with six of them more than doubling in value during that time frame.

Topics Artificial Intelligence World Trade

This Vanguard ETF Makes It Easy to Invest in the "Magnificent Seven" ↗

September 13, 2025